23
Participants
Start Date
September 30, 2005
Primary Completion Date
November 30, 2007
Study Completion Date
July 31, 2009
lenalidomide
Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
Radiation
Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
University of Virginia, Charlottesville
Collaborators (1)
Celgene Corporation
INDUSTRY
Beth Israel Deaconess Medical Center
OTHER
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
University of Virginia
OTHER
Dana-Farber Cancer Institute
OTHER